NCT04149223 Cirrhosis Care Alberta (CCAB): A Pragmatic Type II Hybrid Effectiveness Implementation Trial
| NCT ID | NCT04149223 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Cirrhosis, Liver |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,975 participants |
| Start Date | 2019-06-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,975 participants in total. It began in 2019-06-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Liver cirrhosis is the leading cause of morbidity and premature mortality in patients with digestive disease. There are many gaps in care which contribute to a high rate of hospital readmissions (44 percent at 90 days) and inadequate quality of care. Currently, there is a lack of structured processes to initiate best practice support for medical and broader health needs of high risk patients. The cirrhosis care Alberta program (CCAB) is a 3 year multi-component quality improvement initiative which will aim to improve quality of care, reduce acute care utilization and be satisfactory to both patients and providers. Best practice support will be provided in the areas of: Evidence based management of cirrhosis, alcohol use support, frailty, advance care planning, home-hospital-home transitions including standardized outpatient monitoring and structured urgent access for rapid, on-demand outpatient assessment.
Eligibility Criteria
Inclusion Criteria: * Adults (great than 18 years of age) with a clinical diagnosis of cirrhosis (confirmed by compatible radiology, histology or fibroscan) * Admitted to a study hospital site Exclusion Criteria o Adult patients who do not have cirrhosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04149223 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis, Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04149223 currently recruiting?
Yes, NCT04149223 is actively recruiting participants. Contact the research team at ptandon@ualberta.ca for enrollment information.
Where is the NCT04149223 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT04149223 clinical trial?
NCT04149223 is sponsored by University of Alberta. The trial plans to enroll 3,975 participants.